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INTRODUCTORY PARAGRAPH 
Type I interferons play a key role in systemic lupus erythematosus (SLE) 
pathogenesis1,2 as an “IFN signature” is found in the majority of patients with active SLE3,4. 
Immune complexes are internalized by plasmacytoid dendritic cells (DC) via Fc-gamma 
ReceptorIIA, reach the endosomal compartment and activate IFN-alpha secretion through 
TLR7/9-dependent pathways5,6. Naturally occurring differences in expression of the TLR7/9 
gene7 as well as factors that modulateTLR7/9 expression, including CD154 could therefore 
contribute to SLE pathogenesis. Although its origin is not elucidated CD154 is 
hyperexpressed in SLE patients, and is important for the differentiation of autoantibody-
secreting cells8. We hypothesized that platelets which are an abundant source of CD154, and 
which can mediate proinflammatory effects9,10 could be an actor involved in SLE 
pathogenesis. Platelets from SLE patients are activated in vivo by circulating immune 
complexes which are abundant in SLE sera, via a CD32-dependent mechanism.  Activated 
platelets formed aggregates with antigen-presenting cells in SLE patients and enhanced 
interferon-alpha secretion induced by immune-complexes stimulated plasmacytoid DCs. 
Finally, in vivo depletion of platelets and megakaryocytes in NZBxNZW(F1) lupus prone 
mice improved all parameters assessing disease activity, whereas transfusion of activated 
platelets worsened the disease course. Altogether, these data identify platelets as a mediator of 
SLE pathogenesis and a new therapeutical target.  
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Platelets isolated from SLE patients with a wide range of disease activity 
(Supplementary Table 1) but not from normal individuals, spontaneously expressed CD154 
(CD40 ligand) and CD62P (P-Selectin) at their membrane surface, two markers which are a 
hallmark of platelet activation 9, 11. The increased basal levels of platelet CD62P and CD154 
surface expression were significantly higher in SLE patients (n=20) than in normal blood 
donors (n=20) either before (P= 0.023 and P=0.0009 respectively) or after thrombin activation 
(P=0.0044 and P<0.0001 respectively) (Fig.1a and b). Since CD154 on activated platelets is 
known to be cleaved by a yet unknown mechanism and released in a soluble form (sCD154), 
we hypothesized that the increased levels of sCD154 observed in the blood of SLE patients 12 
(Fig. 1C upper panel) could result from platelet activation. Platelet lysates from SLE patients 
were assayed for their CD154 content and compared with those from normal donors.  SLE 
lysates contained significantly lower levels of CD154 than healthy individuals (P=0.0478). 
Furthermore, lysates from active SLE patients contained lower amounts of CD154 than 
lysates from quiescent SLE patients indicating that disease activity was associated with a 
depletion of platelet-associated CD154 (P=0.025) (Fig 1c, lower panels). This is consistent 
with the observation that serum levels of sCD154 are correlated with the SLE disease activity 
(Fig. 1c, upper panel). Conversely, in SLE patients a reverse correlation was found between 
the levels of CD154 platelet lysates and the levels of serum sCD154 in SLE patients (Fig. 1d) 
strongly suggesting that in SLE serum increased sCD154 levels can partly be attributed to an 
active clipping of the increased CD154 found on SLE platelet membranes. To the best of our 
knowledge this is the first demonstration that increased sCD154 levels found in SLE sera 
could be due to an activation of the megakaryocytic lineage. 
  To understand the mechanisms of platelet activation in SLE patients, we exposed 
platelets from normal controls to several SLE sera. Contrary to allogeneic normal sera or sera 
from other autoimmune diseases such as rheumatoid arthritis (data not shown), SLE sera 
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induced platelet activation in a dose-dependent fashion as assessed by the up-regulation of 
CD62P and CD154 membrane expression (Fig. 2a).  Among the soluble factors possibly 
involved in platelet activation, immune complexes were considered because: 1/ platelets 
express Fc-gamma Receptor IIA (CD32) 13 which is known to interact with immune 
complexes 2/ circulating immune complexes are present in large amounts in SLE blood 
patients 14. As shown in Fig 2b upper panel, platelet activation following incubation with 
sera from SLE patients was inhibited by preincubation of platelets with a blocking anti-CD32 
monoclonal antibody or by depleting the sera of IgG. In contrast, blocking type I interferon or 
CD154, or heat-inactivating sera did not alter their capacity to induce platelet activation. 
Moreover, the addition of immune complexes to normal serum was capable of upregulating 
the membrane expression of CD62P and CD154, mimicking the effects of SLE sera (Fig 2b 
lower panel). To assess whether immune complexes could be found in association with 
platelets in SLE patients, platelet lysates obtained from SLE patients were analyzed by 
probing western blots with anti-human IgG. Whereas IgG could be detected in SLE lysates, 
barely detectable amounts of IgG were found in platelet lysates from RA patients or normal 
controls (Fig 2c upper panel).  Antinuclear antibodies were found among the IgG present in 
platelet lysates from SLE patients but were lacking in those from normal or RA patients even 
when RA patients had detectable serum anti-nuclear antibodies (Fig 2c lower panel). In 
addition after migration of lysates from purified platelets (>99%) on a 1% agarose gel, 
cleaved DNA sensitive to DNAse could be detected in platelet lysates from active SLE 
patients but not in platelet lysates from quiescent diseases (Fig 2c right panel). Together, 
these data support the conclusion that, in SLE patients, platelets are activated by immune 
complexes in a CD32-dependent fashion.  
Once activated, platelets may interact with APCs and form aggregates 15. Monocytes 
(known to act as myeloid DCs in SLE 16) and plasmacytoid DCs could form aggregates with 
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activated platelets as assessed by flow cytometry and confocal microscopy analysis (Fig. 3a, 
b). The occurrence of monocytes-platelets aggregates was significantly higher in the blood of 
SLE patients (n=15) than in normal individuals (n=15) (P=0.002) (Fig.3c). Aggregates 
between platelets and circulating plasmacytoid dendritic cells (pDC), were also more 
numerous than monocyte-platelets aggregates in SLE patients versus healthy controls 
(P<0.001) (Fig. 3c). Incubation of normal platelets activated with SLE sera and APC 
promoted the generation of aggregates partially blocked by an anti-PSGL1 blocking 
monoclonal antibody (Supplementary Fig 1-2). Since plasmacytoid DCs are known to 
interact with circulating ICs from SLE patients and secrete type I interferon in a CD32- and 
TLR9/7-dependent mechanism17,5, we examined the effects of the addition of normal 
activated platelets to purified pDCs from normal donors stimulated by different TLR agonists 
on the secretion of IFN-alpha. While adding activated platelets or ICs alone triggered IFN-
alpha secretion, their simultaneous addition in vitro led to a fivefold increase in IFN-alpha 
secretion (Fig. 3d). Addition of L-cells transfected with CD154 could also potentiate ICs-
mediated IFN-alpha secretion whereas the increase in IFN-alpha secretion could be severely 
downregulated by an anti-CD40 blocking monoclonal antibody thus demonstrating that the 
interaction between CD154 borne by platelets with CD40 borne by pDCs is a prerequisite for 
up-regulating IFN-alpha secretion (Fig. 3d). In addition, we found that activated platelets 
enhanced IFN-alpha secretion upon TLR7/9 plasmacytoid DC specific stimulation 
(Supplementary Fig. 3). Taken together, these data demonstrate an entirely new and key role 
for platelets in SLE pathogenesis, through the ability of platelets to interact with pDCs. To 
demonstrate the relevance of this observation in vivo, NZBxNZW(F1) mice with on-going 
lupus-like disease were depleted of circulating platelets and megakaryocytes. A depleting rat 
monoclonal antibody (n=6) or the isotypic rat control (n=6) was administered to six month-
old mice once a week for 6 weeks. Another group of animals (n=6) was transfused with 
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platelets previously activated in vitro. We found that mice depleted of platelets had 1,5-fold 
lower level of serum ds-DNA IgG (Fig. 4A) and IgM (Fig. 4b) at the completion of the 
observation period when compared to control mice. No difference between the different 
groups in total IgG and IgM levels was found (Supplementary Fig. 4). The kidney function 
remained stable in the group of platelet depleted mice whereas mice receiving isotypic control 
antibody increased their blood urea levels (Fig.4C). This kidney function alteration was more 
pronounced in the group of mice given activated platelets (Fig.4c). After 6 weeks, all mice 
were sacrificed and their kidneys examined under light microscopy. Inflammatory infiltrates 
in the interstitial tissue and the glomeruli were reduced in kidneys from platelet-depleted mice 
than in animals treated with the isotypic control Mab (Fig.4d). In contrast, the kidneys of 
animals transfused with activated platelets displayed dense inflammatory infiltrates, IC 
deposits and intense damages that correlated with the elevation of blood urea (Fig 4e). 
Those data unravel a link between haemostasis and the innate arm of the immune 
system in SLE which is the archetypical human systemic autoimmune disease. Our study 
demonstrates that platelets in SLE patients are activated by circulating immune complexes 
through a mechanism requiring CD32. This activation leads to the formation of platelet 
aggregates with APCs including monocytes and plasmacytoid DCs. This cellular interaction 
strongly potentiated IFN-alpha secretion by immune-complex-stimulated plasmacytoid DCs. 
Moreover, in vivo depletion of platelets in NZBxNZW (F1) lupus prone mice improved 
disease outcome whereas transfusion of activated platelets worsened disease, highlighting 
platelets as a new and promising therapeutical target for patients undergoing active disease. 
We suspect as well, that platelets could be involved in the premature atherosclerosis 
(independent of usual cardiac risk factors) frequently observed in SLE patients, which 
represents a major comorbid condition 18,19. 
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 FIGURE LEGENDS 
Figure 1: Platelets are activated in SLE patients and are the source of the elevated level of 
sCD154 in SLE sera. (a) Flow cytometric analysis of CD62P and CD154 expression on 
freshly isolated platelets from a SLE patient and an healthy volunteer before and after 
thrombin activation (b) Platelet surface CD62P and CD154 expression were evaluated in 20 
SLE patients and 20 healthy individuals. The mean fluorescence intensities corresponding to 
the expression of surface platelet CD62P and CD154 are reported on the vertical axis. Boxes 
indicate 25th and 75th percentiles; error bars, 10th and 90th percentiles.  indicates values 
outside these ranges. P values are indicated in the boxes (Mann Whitney test). (c) sCD154 
blood titers were evaluated in 30 SLE sera, 10 control sera and within the platelet lysates for 
each corresponding patient or control. Boxes indicate 25th and 75th percentiles; error bars, 
10th and 90th percentiles.  indicates values outside these ranges. P values of the 
comparisons are indicated in the boxes. (d) The levels of sCD154 in SLE sera are inversely 
correlated to the levels of CD154 assayed in SLE platelet lysates (Spearman test, Pearson coef 
= 0.86). 
 
Figure 2: Platelets are activated by immune complexes (ICs) via a CD32-dependent 
mechanism. (a) Incubation of normal platelets with a SLE serum from an active patient but 
not with a control serum or a serum from a quiescent SLE patient activates platelets in a dose 
dependent fashion. (b) Left panel: platelets from normal individuals incubated with 10 
different SLE sera were significantly more activated than platelets incubated with normal sera 
(n=6) (P=0.02). Addition of immune complexes to a normal serum promotes platelet 
activation to the same extent as SLE sera does (non parametric Mann_Whitney test). Right 
panel: Pre-incubation of normal platelets with the blocking monoclonal antibody anti-CD32, 
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or depleting SLE sera of IgGs resulted in an inhibition of the ability of the SLE sera to induce 
platelet activation. The figure represents the mean values (+/-SD) of the inhibitions obtained 
in three different experiments using different SLE sera. (c) Upper left panel: Platelets from 
SLE patients interact with ICs. Platelets (2x108) from SLE patients, RA patients or control 
individuals were purified, and their corresponding lysates obtained. Western blot analysis on 
the lysates revealed that binding of IgG by platelets was much higher in SLE patients than in 
controls. Lower left panel: IgG found within the platelet lysates from SLE patients are 
directed against nuclear components as assessed by an indirect immunofluorescence assay. 
Right panel: Platelet lysate from an active SLE patient contained cleaved DNA. Platelet lysate 
was electrophoresed in a 1% agarose gel before staining with bromide ethydium (one 
representative experiment from 5 different). 
 
Figure 3: Activated platelets form aggregates with circulating antigen presenting cells which 
modulate IFN-alpha production. (a) Platelet aggregates were counted using flow cytometry. 
Fresh whole blood was incubated with a mixture of anti-CD62 and  anti-CD42b antibodies to 
stain platelets and an anti-BDCA-2 as a specific marker for pDCs. The proportion of triple 
positive cell (BDCA2+CD42b+CD62p+) represents the proportion of platelets/pDCs 
aggregates. (b) pDCs obtained by negative selection from SLE patients, were stained on a 
slide using anti-BDCA2 (green), anti-CD42b (red) monoclonal antibodies and counterstained 
with DAPI (blue). Analysis by confocal microscopy confirmed that double positive cells 
represent platelets/pDCs aggregates. (c) The proportion of platelets/pDCS and 
platelets/monocytes aggregates are evaluated in 15 SLE patients and 15 controls by flow 
cytometry. The proportion of blood platelets/pDCs and platelets/monocytes aggregates were 
significantly higher in SLE patients when compared to healthy individuals (non parametric 
Mann Whitney test). P values are indicated in the boxes. (d) Purified pDCs (5x105) were 
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incubated with ICs in the presence or absence of activated platelets (5x106) for 24 hours. In 
one condition blocking monoclonal anti-CD40 antibody (Mab89) was added at culture onset. 
IFN-alpha levels released in supernatants by pDCs were measured by ELISA. The mean 
values (+/-SD) of three different independent experiments are shown. 
 
Figure 4: In vivo involvement of platelets in lupus pathogenesis in the mouse  
NZBxNZW(F1) model.  (a) Six month old NZB/NZW(F1) (n=6) were injected iv with 3μg/g 
of anti-CD42b p0p3/4 mAb (Platelet-depleted) or with 3µg/ml of an isotypic control mAb 
(Isotypic control) on day 0 and once a week for six weeks. A third group was composed of six 
NZB/NZW(F1) given at day 0 and once a week one milliliter of 2x107 in vitro activated 
platelets (Platelet transfusion). Serum was harvested on day 0 and six weeks later before 
assayed for anti-DNA IgG  or anti-DNA IgM blood levels (b). Data are expressed as the mean 
values of six different mice. (c) Blood urea levels were measured at day 0 and at six week. (d) 
At week 6, mice were sacrificed and kidneys were analyzed under light microscopy (lower 
panels). Upper panels depict immune complexes deposit within the glomeruli. (e) 
Immunohistologic and histologic assessment of platelet-dependent lupus nephritis.  
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Patients, materials, and methods 
 
1/ Patients 
SLE patients (n=37) who fulfilled four or more of the 1982 revised ACR criteria for the 
disease, were enrolled in this study. The group of healthy subjects (controls) comprised our 
medical staff free of any auto-immune or infectious diseases. Patients with anti-phospholipid 
antibodies, and/or thrombopenia were excluded from the study. Table S1 summarized 
demographic and clinical characteristics. An active patient is a patient at diagnosis or a patient 
with a 3 point-increased of it SLE Disease Activity Index when compared to it previous one.  
 
2/ Platelets 
Platelet-rich plasma (PRP) 
Preparation of platelet-rich plasma: PRP was prepared by centrifugation of citrated blood 
samples at 1500 rpm for 10mn. Platelets were counted using a CellDyn 3500 hemocytometer 
and PRP was adjusted to the desired concentration by addition of Tyrode’s buffer (134 mM 
NaCl, 2,9 mM KCl,0,34 mM Na2PO4, 12mM NaHC03, 20 mM HEPES, 1mM MgCl2, 5mM 
glucose, [pH 7,2]). 
Washed platelets 
Preparation of washed platelets: PRP was added 1/10 vol/vol ACD-A (25g/l Tris-sodium 
citrate, 20g/l D-Glucose, and 15g/l Citric acid), and spun at 1500 rpm for 10mn. The platelet 
pellet was resuspended in Tyrode’s buffer and 1μM PGE1 (final concentrations) and 80 U/ml 
apyrase were added. Platelets were counted and adjusted to the desired concentration by 
addition of Tyrode’s buffer. 
Platelets activation 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
08
.1
52
8.
1 
: P
os
te
d 
21
 J
an
 2
00
8
To activate platelets, 0,5 IU/ml of thrombin (Sigma, L’isle d’abeau, France), final 
concentration was added to platelets in Tyrode’s buffer.  
Platelet lysate 
Non activated or activated with thrombin platelets (1x108) were lyzed in Tyrode’s buffer 
supplemented with Triton X-100 1% during 30mn at room temperature (RT) in the presence  
of leupeptin 20μg/ml (Sigma). The lysate was then centrifuged 10 mn at 10000 rpm at room 
temperature. Supernatants were harvested and frozen at -20°C until used. 
Analysis of DNA fragmentation 
Jurkat cells (108) have been incubated for 4h with human recombinant Fas-L IgG (Alexis, 
Paris, France). Platelets (6x108 per condition) or apoptotic Jurkat cells were lysed and DNA 
extracted by ethanol precipitation before migration in a 1% agarose gel as described 
previously (ref) 
 Western blot analysis 
Platelets (108) lysates were separated on a 10% SDS-PAGE in reducing conditions and 
transferred to a polyvinyldifluoride membrane (Amersham, Buckinghamshire, England), as 
described previously (ref). Ig were revealed by the use of peroxydase labelled human 
polyclonal anti-Ig and the luminol fluorescent kit (ECL, Amersham). 
 Determination of anti-nuclear autoantibodies 
Antinuclear antibodies were detected by indirect immunofluorescence on Hep-2 cells lines 
(Institut Jacques Boy, Reims, France). 
 
3/ Immune complexes 
Immune complexes were generated as published elsewhere{Bave, 2000 #64}. Briefly, serum 
samples from SLE patients were obtained and anti-double-stranded-DNA and anti-
ribonucleoproteins levels were measured using a commercially available ELISA kits (Fidis, 
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BMD, France). All samples were filtered through a 0.45-µm polyvinylidene fluoride syringe 
before purification as described previously. The T cell lines Jurkat were treated at 
1x106cells/ml by IgG FasLigand (Alexis,Läufelfingen, Switzerland), 100ng/ml final 
concentration, for 4h at 37°C. Cells were then washed once before using 
 
4/ Cell preparation 
Human PBMC were isolated from buffy coats by Ficoll gradient centrifugation. Primary 
human plasmacytoid dendritic cells (pDCs) were purified from the PBMCs by 
immunomagnetic-beads positive selection using BDCA-4 microbeads following manufacturer 
instructions (Miltenyi Biotec). Briefly, PBMC were stained with anti-BDCA-4 antibody 
coupled to colloidal paramagnetic microbeads and passed through a magnetic separation 
column twice (LS and RS column; Miltenyi Biotec). In some experiments, pDCs were then 
cell sorted using flow cytometry (FACSAria Cell sorting system, Becton-Dickinson, Pont-de-
Claix, France) to reach purities > 95%.  
All cells were cultured in complete medium (RPMI 1640, 2mM L-Glutamine, 100 U /ml 
penicillin/streptomycin, and 8% low endotoxin FCS) and maintained at 37° and 5% CO2.  
Stimulating conditions 
Isolated pDCs were cultured in 96-well round-bottom plates (Nunc, Roskilde, Denmark), 
(7.5x104 cells in 200 µl medium/well) with platelets (5x106) in the presence of the different 
stimuli. 
 
5/ Flow cytometry 
 
Washed platelets or plasma rich platelets (104/μl) were incubated for 15mn at room 
temperature in the dark with 20μl of FITC-conjugated monoclonal antibodies specific for 
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CD61 (GP IIIa) or 20μl PE-conjugated monoclonal antibodies specific for CD40L, or 20μl 
APC-conjugated monoclonal antibodies specific for CD62p (P-selectin), all from Becton 
Dickinson. All staining were run by using the same instrument settings. 
 
6/ Confocal microscopy 
PBMCs were isolated from SLE patients by Ficoll gradient separation and pDCs were 
enriched by negative selection. Cells (105) were let to adhere for 10 mn at room temperature 
onto poly-L-lysin-coated slides (Kindler, Freiburg, Germany). Then cells have been fixed by 
dipping slides in PBS containing 4% formaldehyde for 15mn, washed twice in PBS-1% 
bovine serum albumin and finally stained with a primary mouse anti-human GPIb (Wm23 
antibody anti-GPIb, kindly given by M. Berndt, Melbourne, Australia) in PBS-1% bovine 
serum albumin, during 1h at room temperature. Slides were washed twice with PBS and 
stained with the secondary Alexa-568-conjugated goat anti-mouse antibody in PBS-1% 
bovine serum albumin during 1h at room temperature. Slides were washed with PBS and 
stained with anti-BDCA2-FITC and DAPI during 1h at RT. After washing with PBS, slides 
were dried and mounted with Dakocytomation mounting medium (Dakocytomation, 
Denmark). Images were acquired and processed on a confocal microscope (Leica, Germany) 
with a X63 objective. 
 
7/ ELISA 
Commercially available kits were used to quantify IFN-alpha, and sCD154 (all from Bender 
MedSystems, Vienna, Austria) and were used according to the manufacturer’s instructions. 
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Six month old NZB/NZW(F1) (n=6) were injected iv with 3μg/g of monoclonal anti-CD42b 
p0p3/4 (plt-depleted) or not (controls) on day 0 and once a week for six weeks. The platelet-
depleting antibody (a mixture of clones p0p3 and p0p4) was generated as previously 
described {Bergmeier, 2000 #80}. A third group was composed of six NZB/NZW(F1) given 
at day 0 and once a week one milliliter of 2x107 activated platelets/ml. Serum was harvested 
on day 0 and once a week and tested for anti-DNA IgG and IgM blood levels. Levels of total 
anti-dsDNA IgG and IgM Abs were measured using standard ELISA as described previously 
{Goulvestre, 2005 #81}. Blood urea levels were measured at day 0 and week 6 using standard 
techniques for laboratory determinations. At week 6, mice were sacrificed and kidneys were 
analyzed by light microscopy as described previously 
 
9/ Statistical analysis 
Pearson's correlation analysis was used to measure correlation between 2 parameters. 
Comparisons between groups were performed using the nonparametric Mann-Whitney U test 
with a level of significance at P 0.05. The tests were performed with the statistical software 
Statistica Inc. (Statsoft, Tucson, AZ). 
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Figure 3A
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Figure 3B
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Table 1. Summary of the demographic, clinical, and biological characteristics and treatments 
of SLE patients in the study 
 
 
 
 
SLE = Systemic lupus erythematous ; ACR= American College of Rheumatology ; SLEDAI 
= SLE Disease Activity Index ; A= musculoskeletal system ; Sk= mucocutaneous lesions ; 
Pred. = Prednisone; HCQ = Hydroxychloroquine; Bl= hematologic abnormality; P= 
Pericarditis; NP = neuropsychiatric disorders; K = renal disease; MMF = mycophenolate 
mofetil; Me = Methotrexate 
*At the time of blood sampling 
patient/sex/age 
disease flare 
manifestations SLEDAI score* treatment ANA anti-DNA 
1/F/32 Sk,A,Bl 7 Pred 2000 239 
2/F/28 Sk,A,R 4 Pred,HCQ,MMF 250 57 
3/M/33 A,P,NP 13 Pred,MMF 8000 92 
4/F/49 Sk,A,R 6 Pred,MMF 500 29 
5/F/47 Sk,A,R 0 Pred,MMF 4000 7 
6/F/33 Sk,A,Bl 2 Pred,HCQ 16000 25 
7/F/29 Sk,A 0 None 250 1 
8/F/35 Sk,A 8 Pred,HCQ 2000 42 
9/F/27 Sk,A 10 None 8000 647 
10/F/42 Sk,A,Bl 0 Pred,HCQ 250 2 
11/F/52 Sk,A 4 HCQ 2000 19 
12/F/26 Sk,A 4 Pred 250 24 
13/M/46 A,Sk 0 Pred 16000 13 
14/F/44 Sk,A 10 HCQ 1000 55 
15/F/29 Sk 2 Pred,HCQ 32000 12 
16/F/39 Sk,A 8 Pred,Me 2000 52 
17/F/28 Sk 0 None 500 18 
18/F/30 Sk,R 0 MMF 500 67 
19/M/30 A,R 2 None 500 35 
20/F/45 A,P 0 None 1000 12 
21/F/56 Sk,Bl 4 Pred,HCQ 1000 16 
22/F/32 Sk,A 0 None 1000 1 
23/F/29 A,R 4 Pred,HCQ,MMF 2000 832 
24/F/42 A,R 4 Pred,HCQ 2000 6 
25/F/45 Sk,Bl 5 None 2000 136 
26/F/32 A,Sk 0 None 2000 30 
27/M/38 A,Bl 3 Pred 250 113 
28/F/36 Sk,A 2 Pred,HCQ 8000 14 
29/F/70 A,Sk 0 HCQ 250 1 
30/F/47 A,Bl 0 HCQ,Pred 250 9 
31/F/35 Sk,A 4 HCQ,Pred 500 9 
32/F/26 Sk,NP 8 Pred,HCQ,MMF 1000 32 
33/M/54 Sk,Bl 3 None 8000 130 
34/F/34 Sk,Bl 4 Pred,HCQ 500 7 
35/M/32 Bl,A 0 Pred 250 9 
36/F/24 Sk,A 0 Pred,HCQ 500 32 
37/F/28 A,Bl 2 Pred,HCQ 1000 27 
38/F/42 R,Sk 10 Pred,HCQ,MMF 1000 47 
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